Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$ARQT Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.11 up 184.62% YoY • Reported revenue of $129.86M up 59.33% YoY • Arcutis Biotherapeutics, Inc. raised its full-year 2026 net product sales guidance to a range of $525 million to $540 million, reflecting the company's expectation for continued growth and momentum throughout 2026.

Price since post

Full Details

Advertisement|Remove ads.